Summary
Plain language summaries (PLS), also known as lay summaries and trial results summaries, educate participants and the public
about clinical trial results in an easy-to-understand manner. Creating a PLS involves translating complex, technical information from regulatory documents into a short summary using non-promotional and unbiased language. These summaries are generally written at a 6th-to-8th-grade US reading level and avoid medical terminology and industry jargon. Current challenges sponsors face include the creation of a consistent and transparent PLS portfolio that revolves around the development of a reliable template. This template should consider both regulatory requirements and patient-centric health literacy principles that increase understanding. Sponsors preparing to meet short deadlines for PLS submission can incorporate best practices and implementation strategies presented in this white paper that allow for PLS drafting ahead of clinical study report (CSR) finalization.
Register to download
Plain Language Summaries - Keeping the End in Mind: Key Considerations for Creating Plain Language Summaries
You may also be interested in:
Blog
Navigating Global Regulatory CMC Processes During Public Health Crises
Chemistry, manufacturing, and controls (CMC) regulations are a critical part of the drug development path and the ongoing production and distribution…
White Paper
Chemistry, Manufacturing, and Controls (CMC) in Drug Development and Life Cycle Management
This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development.…
Blog
New Ways to Think Strategically About Clinical Trial Transparency
Clinical teams face increasing pressure to adapt to recent advances within trial transparency. Clinical trial transparency now incorporates sharing…